{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:54:13Z","timestamp":1783137253082,"version":"3.54.6"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00296-013-2857-2","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T08:56:29Z","timestamp":1378889789000},"page":"101-109","source":"Crossref","is-referenced-by-count":61,"title":["As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout"],"prefix":"10.1007","volume":"34","author":[{"given":"A.-K.","family":"Tausche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Forkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kopprasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bielitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"2857_CR1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/acr.21791","volume":"65","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Miller ER 3rd, Gelber AC (2013) Body mass index, obesity, and prevalent gout in the United States in 1988-1994 and 2007\u20132010. Arthritis Care Res (Hoboken) 65:127\u2013132","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2857_CR2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M et al (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 67:960\u2013966","journal-title":"Ann Rheum Dis"},{"key":"2857_CR3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","volume":"24","author":"EU Smith","year":"2010","unstructured":"Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM (2010) Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 24:811\u2013827","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2857_CR4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00393-011-0953-9","volume":"71","author":"AK Tausche","year":"2012","unstructured":"Tausche AK, Manger B, Muller-Ladner U, Schmidt B (2012) Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia. Z Rheumatol 71:224\u2013230","journal-title":"Z Rheumatol"},{"key":"2857_CR5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2952","volume":"12","author":"N Busso","year":"2010","unstructured":"Busso N, So A (2010) Mechanisms of inflammation in gout. Arthritis Res Ther 12:206","journal-title":"Arthritis Res Ther"},{"key":"2857_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T et al (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 10:117","journal-title":"Health Qual Life Outcomes"},{"key":"2857_CR7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","volume":"50","author":"PP Khanna","year":"2011","unstructured":"Khanna PP, Perez-Ruiz F, Maranian P, Khanna D (2011) Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 50:740\u2013745","journal-title":"Rheumatology (Oxford)"},{"key":"2857_CR8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","volume":"52","author":"LK Stamp","year":"2013","unstructured":"Stamp LK, Chapman PT (2013) Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 52:34\u201344","journal-title":"Rheumatology (Oxford)"},{"key":"2857_CR9","doi-asserted-by":"crossref","first-page":"e27817","DOI":"10.1371\/journal.pone.0027817","volume":"6","author":"H Ito","year":"2011","unstructured":"Ito H, Abe M, Mifune M et al (2011) Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS ONE 6:e27817","journal-title":"PLoS ONE"},{"key":"2857_CR10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.numecd.2007.02.011","volume":"17","author":"P Strazzullo","year":"2007","unstructured":"Strazzullo P, Puig JG (2007) Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17:409\u2013414","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2857_CR11","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.2174\/1381612811319130011","volume":"19","author":"D Grassi","year":"2013","unstructured":"Grassi D, Ferri L, Desideri G et al (2013) Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des 19:2432\u20132438","journal-title":"Curr Pharm Des"},{"key":"2857_CR12","doi-asserted-by":"crossref","unstructured":"Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E (2013) Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. doi: 10.1136\/annrheumdis-2012-202421 [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2012-202421"},{"key":"2857_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.33369","volume":"64","author":"T Neogi","year":"2012","unstructured":"Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA (2012) Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum 64:327\u2013338","journal-title":"Arthritis Rheum"},{"key":"2857_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","volume":"5","author":"J George","year":"2009","unstructured":"George J, Struthers AD (2009) Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 5:265\u2013722","journal-title":"Vasc Health Risk Manag"},{"key":"2857_CR15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/TCRM.S5701","volume":"5","author":"J George","year":"2009","unstructured":"George J, Struthers A (2009) The role of urate and xanthine oxidase in vascular oxidative stress: future directions. Ther Clin Risk Manag 5:799\u2013803","journal-title":"Ther Clin Risk Manag"},{"key":"2857_CR16","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman A, Ang DS, Ogston S, Lang CC, Struthers AD (2010) Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375:2161\u20132167","journal-title":"Lancet"},{"key":"2857_CR17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2012.09.066","volume":"61","author":"S Rekhraj","year":"2013","unstructured":"Rekhraj S, Gandy SJ, Szwejkowski BR et al (2013) High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 61:926\u2013932","journal-title":"J Am Coll Cardiol"},{"key":"2857_CR18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: diagnosis. report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301\u20131311","journal-title":"Ann Rheum Dis"},{"key":"2857_CR19","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: management. report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"},{"key":"2857_CR20","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD et al (2012) 2012 american college of rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447\u20131461","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2857_CR21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 american college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431\u20131446","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2857_CR22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10067-010-1457-8","volume":"29","author":"TL Jansen","year":"2010","unstructured":"Jansen TL, Richette P, Perez-Ruiz F et al (2010) International position paper on febuxostat. Clin Rheumatol 29:835\u2013840","journal-title":"Clin Rheumatol"},{"key":"2857_CR23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/eurheartj\/14.2.160","volume":"14","author":"M Karamanoglu","year":"1993","unstructured":"Karamanoglu M, O\u2019Rourke MF, Avolio AP, Kelly RP (1993) An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 14:160\u2013167","journal-title":"Eur Heart J"},{"key":"2857_CR24","first-page":"1381","volume":"34","author":"HR Schumacher","year":"2007","unstructured":"Schumacher HR, Taylor W, Joseph-Ridge N et al (2007) Outcome evaluations in gout. J Rheumatol 34:1381\u20131385","journal-title":"J Rheumatol"},{"key":"2857_CR25","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Martin I, Canteli B (2007) Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 34:1888\u20131893","journal-title":"J Rheumatol"},{"key":"2857_CR26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/ard.2010.139899","volume":"70","author":"N Dalbeth","year":"2011","unstructured":"Dalbeth N, Schauer C, Macdonald P et al (2011) Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 70:597\u2013604","journal-title":"Ann Rheum Dis"},{"key":"2857_CR27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0076-6879(00)05515-4","volume":"305","author":"RC Allen","year":"2000","unstructured":"Allen RC, Dale DC, Taylor FB Jr (2000) Blood phagocyte luminescence: gauging systemic immune activation. Methods Enzymol 305:591\u2013629","journal-title":"Methods Enzymol"},{"key":"2857_CR28","first-page":"389","volume-title":"Bioluminescence and chemiluminescence: current status","author":"T Mets\u00e4-Ketel\u00e4","year":"1991","unstructured":"Mets\u00e4-Ketel\u00e4 T (1991) Luminescent assay for total peroxyl radical-trapping capability of plasma. In: Stanley P, Kricka L (eds) Bioluminescence and chemiluminescence: current status. Wiley, Chichester, pp 389\u2013392"},{"key":"2857_CR29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0076-6879(90)86141-H","volume":"186","author":"RL Levine","year":"1990","unstructured":"Levine RL, Garland D, Oliver CN et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464\u2013478","journal-title":"Methods Enzymol"},{"key":"2857_CR30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosissup.2012.10.007","volume":"14","author":"S Kopprasch","year":"2013","unstructured":"Kopprasch S, Bornstein SR, Schwarz PE, Bergmann S, Julius U, Graessler J (2013) Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients. Atheroscler Suppl 14:157\u2013160","journal-title":"Atheroscler Suppl"},{"key":"2857_CR31","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehq165","volume":"31","author":"F Mattace-Raso","year":"2010","unstructured":"Mattace-Raso F, Hofman A, Verwoert GC et al (2010) Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: \u2018establishing normal and reference values\u2019. Reference values for arterial stiffness\u2019 collaboration. Eur Heart J 31:2338\u20132350","journal-title":"Eur Heart J"},{"key":"2857_CR32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","volume":"125","author":"A Whelton","year":"2013","unstructured":"Whelton A, MacDonald PA, Chefo S, Gunawardhana L (2013) Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 125:106\u2013114","journal-title":"Postgrad Med"},{"key":"2857_CR33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/BOR.0b013e3282f4b1ed","volume":"20","author":"JG Puig","year":"2008","unstructured":"Puig JG, Mart\u00ednez MA (2008) Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 20:187\u2013191","journal-title":"Curr Opin Rheumatol"},{"key":"2857_CR34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","volume":"14","author":"K Lottmann","year":"2012","unstructured":"Lottmann K, Chen X, Schadlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 14:195\u2013203","journal-title":"Curr Rheumatol Rep"},{"key":"2857_CR35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/07853890.2011.653393","volume":"44","author":"AC Montezano","year":"2012","unstructured":"Montezano AC, Touyz RM (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44:2\u201316","journal-title":"Ann Med"},{"key":"2857_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-1759(99)00146-5","volume":"232","author":"C Dahlgren","year":"1999","unstructured":"Dahlgren C, Karlsson A (1999) Respiratory burst in human neutrophils. J Immunol Methods 232:3\u201314","journal-title":"J Immunol Methods"},{"key":"2857_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.vph.2012.02.012","volume":"56","author":"A Schramm","year":"2012","unstructured":"Schramm A, Matusik P, Osmenda G, Guzik TJ (2012) Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol 56:216\u2013231","journal-title":"Vascul Pharmacol"},{"key":"2857_CR38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.numecd.2007.02.011","volume":"17","author":"P Strazzullo","year":"2007","unstructured":"Strazzullo P, Puig JG (2007) Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17:409\u2013414","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2857_CR39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.yjmcc.2008.02.275","volume":"44","author":"C Wunderlich","year":"2008","unstructured":"Wunderlich C, Schober K, Schmeisser A et al (2008) The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol 44:938\u2013947","journal-title":"J Mol Cell Cardiol"},{"key":"2857_CR40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/rheumatology\/kes169","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo CF, Yu KH, See LC et al (2013) Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52:111\u2013117","journal-title":"Rheumatology (Oxford)"},{"key":"2857_CR41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keq095","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, Yu KH, Luo SF et al (2010) Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 49:1189\u20131196","journal-title":"Rheumatology (Oxford)"},{"key":"2857_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jacc.2005.08.052","volume":"47","author":"ME Safar","year":"2006","unstructured":"Safar ME, Thomas F, Blacher J, Nzietchueng R, Bureau JM, Pannier B, Benetos A (2006) Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 47:72\u201375","journal-title":"J Am Coll Cardiol"},{"key":"2857_CR43","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jacc.2005.07.037","volume":"46","author":"CM McEniery","year":"2005","unstructured":"McEniery CM, Yasmin Hall IR, Qasem A, Wilkinson IB, Cockcroft JR, ACCT Investigators (2005) Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 46:1753\u20131760","journal-title":"J Am Coll Cardiol"},{"key":"2857_CR44","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296\u20131305","journal-title":"N Engl J Med"},{"key":"2857_CR45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","volume":"48","author":"DE Weiner","year":"2006","unstructured":"Weiner DE et al (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48:392\u2013401","journal-title":"Am J Kidney Dis"},{"key":"2857_CR46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2011.04.004","volume":"51","author":"UZ Malik","year":"2011","unstructured":"Malik UZ, Hundley NJ, Romero G et al (2011) Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 51:179\u2013184","journal-title":"Free Radic Biol Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2857-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2857-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2857-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T18:54:04Z","timestamp":1563908044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2857-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2857-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}